{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007074","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.514211+00:00","generated_at":"2026-05-22T01:53:06.117942+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA grants RMAT designation to MeiraGTx's AAV-GAD for Parkinson's disease","bullets":["RMAT designation based on data from three clinical studies (Phase 1 n=12, Phase 2 n=45, dose-ranging n=14).","AAV-GAD showed significant benefit on UPDRS Part 3 motor endpoint in double-blind sham-controlled trials.","Hologen AI analysis indicated disease-modifying brain circuitry changes, first in sham-controlled Parkinson's study.","RMAT includes Fast Track and Breakthrough Therapy benefits, rolling review, and potential Priority Review for BLA.","MeiraGTx plans to work closely with FDA to advance this one-time gene therapy for Parkinson's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007074","json":"https://secwatch.observer/filing/0001558370-25-007074.json","markdown":"https://secwatch.observer/filing/0001558370-25-007074.md","text":"https://secwatch.observer/filing/0001558370-25-007074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837025007074/0001558370-25-007074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837025007074/mgtx-20250509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:53:06.117942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}